Filing Scope and Business Context
The supplied filing is a Form 10-Q for B-Maven, Inc., a Nevada development-stage company engaged in developing and selling the E-Scentual skin-care product line. It covers the quarter and nine months ended March 31, 2014, with a June 30 fiscal year-end. The request metadata identifies Iqstel Inc. and “2013 Q3,” which does not match the registrant or reporting period shown in the filing.
The company reported 10,000,000 common shares outstanding as of May 12, 2014, had one employee, and identified itself as a shell company and smaller reporting company.
Financial Performance and Position
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Revenue | $3,905 vs. $1,130 | $7,707 vs. $1,755 |
| Cost of goods sold | $503 vs. $213 | $924 vs. $318 |
| Gross profit | $3,402 vs. $917 | $6,783 vs. $1,437 |
| Gross margin | 87.1% vs. 81.2% | 88.0% vs. 81.9% |
| Operating expenses | $7,146 vs. $7,552 | $26,547 vs. $31,266 |
| Interest expense | $282 vs. none | $601 vs. none |
| Net loss | $4,026 vs. $6,635 | $21,165 vs. $30,629 |
At March 31, 2014, total assets were $93, consisting primarily of inventory; cash and cash equivalents were zero. Total liabilities were $40,460, including $7,086 of accrued expenses, $5,000 of customer advances, $619 of unrelated-party loans, and $27,755 of related-party loans. Stockholders’ deficit was $40,367; the accumulated development-stage deficit was $27,766.
Operating activities used $28,374 of cash during the nine months, funded by $28,374 of financing proceeds, principally related-party loans. Ending cash was zero. The company had no bank line of credit or other committed financing arrangement.
Material Changes Versus Prior Comparable Period
- Nine-month revenue increased by $5,952, or approximately 339%, to $7,707; quarterly revenue increased by $2,775, or approximately 246%, to $3,905.
- Gross margin improved to 88.0% for the nine-month period from 81.9%, and to 87.1% for the quarter from 81.2%.
- Nine-month operating expenses declined by $4,719, primarily from lower consulting, professional, sample, and amortization costs.
- Net loss narrowed by $9,464 for the nine months and by $2,609 for the quarter, although the company remained unprofitable.
- Related-party borrowing increased materially from none at June 30, 2013 to $27,755 at March 31, 2014. The company subsequently received approximately $6,100 of additional related-party loans on May 2, 2014.
- Product formulas and samples were fully amortized as of March 31, 2014.
Guidance, Outlook, Risks, and Unusual Items
The company provided no formal financial guidance. Management stated that commercial-scale product development could cost more than $100,000 and estimated a need for at least $50,000 to $100,000 for raw materials, labeling, packaging, marketing, and advertising. It plans to seek additional equity or debt financing, but has no financing commitment.
The financial statements include a going-concern warning. Management disclosed negative working capital, no cash, limited revenue, no committed capital sources, and substantial doubt about the company’s ability to continue without profitable operations or additional financing. Management indicated that current resources may support operations for only three to six months and that failure to obtain funding could require a material reduction or cessation of operations.
Key risks include limited operating history and market acceptance, dependence on third-party manufacturers and consultants, competition from substantially better-funded skin-care companies, lack of patent or trademark protection, possible product-liability claims, regulatory uncertainty, reliance on related-party financing, dilution from future securities issuances, and the absence of an established liquid trading market. The company also reported one director who is its president and CEO, with no independent audit or compensation committees.
No legal proceedings, unregistered equity sales, defaults on senior securities, or off-balance-sheet arrangements were reported. Management stated that disclosure controls were effective as of March 31, 2014 and that no material changes occurred in internal controls during the quarter.
Investor Verification Checklist
- Confirm the correct issuer and period: the filing is for B-Maven, Inc. for the period ended March 31, 2014, not Iqstel Inc. or an explicitly labeled 2013 third quarter.
- Verify the zero cash balance, $40,460 of liabilities, $40,367 stockholders’ deficit, and the composition and terms of related-party loans.
- Assess whether the company obtained the additional $50,000 to $100,000 or other financing needed for commercial production and ongoing operations.
- Validate the sustainability and collectability of the reported revenue, including the limited sales base and reliance on product samples, selective placement, and grass-roots marketing.
- Review subsequent financing, repayment dates, interest terms, and any additional related-party transactions after March 31, 2014.
- Evaluate the going-concern disclosure, the company’s shell-company status, lack of intellectual-property registrations, and the absence of an established trading market.